Ask AI
ProCE Banner Series

Optimizing Transplant Outcomes Through Contemporary CMV Management: Strategies to Address Clinical Challenges in Treatment of Refractory or Resistant Disease

Join us for this live session presented by expert faculty to learn about optimizing antiviral regimens for CMV infections in HCT recipients.

Continuing Medical and Professional Education: 2026 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR are sponsored by the Medical College of Wisconsin.

Claim credit for this event: https://tandem.virtual-meeting.org/programme/session/119419 

  AMA
Who Should Attend

This activity is intended for clinical specialists, including physicians, clinical pharmacists, advanced practice providers, and other healthcare professionals who care for HCT recipients with CMV infections.

All Events

Optimizing Transplant Outcomes Through Contemporary CMV Management: Strategies to Address Clinical Challenges in Treatment of Refractory or Resistant Disease

Upcoming Events

February

05

2026

7:00 AM - 8:00 AM Mountain Time (MT)

In-person

Salt Palace Convention Center, 100 S W Temple St, Salt Lake City, Utah 84101

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners in optimizing antiviral regimens for CMV infections in HCT recipients.

Target Audience
This activity is intended for clinical specialists, including physicians, clinical pharmacists, advanced practice providers, and other healthcare professionals who care for HCT recipients with CMV infections.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Describe the comprehensive burden of CMV replication on post-HCT clinical courses
  • Update strategies for timely identification of HCT recipients with, or at risk for, CMV infections with inadequate response to initial therapies
  • Modify antiviral therapy in HCT recipients experiencing treatment-limiting toxicities
  • Optimize antiviral regimens for treatment-refractory CMV infections in post-HCT settings

Accreditation

Joint Accreditation Statement

Joint Accreditation

 

 

 

ACCME Accreditation Statement

The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education to physicians.

AMA Credit Designation

The Medical College of Wisconsin designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by

Provided by the Medical College of Wisconsin

Medical College of Wisconsin

Supporters

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Takeda Pharmaceuticals U.S.A., Inc.

For customer support please click here.

Mailing Address:

 

Decera Clinical Education
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191